A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin (RBV) in Subjects With (Genotype 1) Hepatitis C Who Did Not Respond to Previous Treatment.
Phase of Trial: Phase III
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 17 Aug 2012 Additional lead trial investigator (Fumitaka Suzuki) identified as reported by ClinicalTrials.gov.
- 07 Mar 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 07 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.